Jacqueline S. Garcia

Author

Also Known As

Garcia, J.S., Garcia, Jacqueline S., J García, J. Garcia, J. S. Garcia, Jacqueline Garcia, Jacqueline S Garcia, Jacqueline S. Garcia, Jacqueline Suen Garcia, Jacqueline S. Garcia

377

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Harvard University University of Chicago AbbVie (United States)

About

Jacqueline S. Garcia is an author at Dana-Farber Cancer Institute specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	21	1.2K
2	Health Sciences	7	7	410
3	Engineering	1	1	302
4	Natural Sciences	1	1	16
5	Public Health	1	1	35

Jacqueline S. Garcia

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, New England Journal of Medicine	2020	2.6K
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice Elizabeth C. Townsend, Mark A. Murakami, Alexandra Christodoulou, Cancer Cell Knockout MouseXenotransplantationXenografts Enables DiscoveryEngineeringIn Vivo System	2016	302
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms Debra Van Egeren, Javier Escabi, Maximilian Nguyen, Cell stem cell	2021	204
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski, Cancer Cell Hematological MalignancyBh3 MimeticsMitochondrial FunctionMixed-phenotype Acute LeukemiaAcute Myeloid Leukemia	2020	165
Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, American Journal of Hematology	2024	165
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Journal of Clinical Oncology	2021	156
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i> -Mutated Myeloid Malignancies Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, Blood Cancer Discovery	2023	114
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial Naval Daver, Monique Dail, Jacqueline S. Garcia, Blood Mixed-phenotype Acute LeukemiaPharmacotherapyTranslational PharmacologyMyeloid NeoplasiaHematological Malignancy	2022	94
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes Amer M. Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Blood	2023	87
Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Clinical Cancer Research	2022	82

Page 1